The number of adult heart transplant candidates waiting at the most urgent status 1A has increased over time despite the expansion of geographic sharing of hearts in 2006. We aimed to determine whether candidates listed with inotropes contribute to the excess status 1A candidates.
H
eart transplant candidates are given priority for transplant based on status, a 3-tiered candidateranking system designed with the intention of prioritizing medically urgent candidates. 1 Status is determined by the therapies a candidate is receiving, based on the premise that candidates nearer death will require more life-sustaining therapies. The highest priority status 1A patients are expected to have short life expectancies without transplant and must be receiving intensive life support therapy, such as acute mechanical circulatory support (MCS) or high-dose inotrope therapy. 1 In July 2006, the Organ Procurement and Transplant Network expanded the geographic sharing of donor hearts, enlarging the zone of priority for 1A candidates. This policy change met its intended goal of increasing the rate of transplantation for status 1A candidates. [2] [3] [4] The adult heart allocation system now faces a new challenge because the total number of candidates both listed and waiting at status 1A have increased substantially since 2006, despite the geographic sharing policy. [5] [6] [7] By 2015, 67% of heart transplant recipients were status 1A at the time of transplant. 8 Current explanations for the increase in status 1A candidates include increased use of continuous-flow left ventricular assist devices (CF-LVADs) and status 1A exceptions. 5, [7] [8] [9] [10] However, other changes in transplant program-listing practice could be contributing to the excess number of status 1A candidates. It has been suggested that transplant centers have become more likely to game the waitlist by using unnecessary multiple inotrope therapy to bump nonurgent candidates up to status 1A. 6, 11, 12 In this study, we describe trends over time in the use of inotropes to list adult heart transplant candidates and in the medical urgency of candidates listed with inotropes. Specifically, we aimed to determine whether less urgent candidates overtreated with high-dose or multiple inotropes were significantly contributing to the excess number of status 1A candidates.
METHODS Candidate Population and Data
This study used data from the Scientific Registry of Transplant Recipients. The Scientific Registry of Transplant Recipients data system includes data on all donor, waitlisted candidates, and transplant recipients in the United States, submitted by the members of the Organ Procurement and Transplant Network. The Health Resources and Services Administration, US Department of Health and Human Services, provides oversight to the activities of the Organ Procurement and Transplant Network and Scientific Registry of Transplant Recipients contractors. Data were collected from the initial registrations of all adult heart-alone US transplant candidates added to the waitlist between January 1, 2000, and December 31, 2015. We limited our analysis to initial registration data because initial listing represents a standard reference point in the care of advanced heart failure patients, and the initial registration forms contain the most complete candidate information.
All available candidate data from the Transplant Candidate Registration forms was collected. Medical data included age, weight, height, sex, body mass index, cardiac diagnosis, blood type, renal function, history of diabetes mellitus, cerebrovascular disease, malignancy, cardiac surgery, smoking, and defibrillator placement. Functional status was recorded on the Karnofsky 11-point performance status scale, which has been validated in heart failure patients. 13, 14 Socioeconomic variables included citizenship, race, insurance type, education, and work history. Hemodynamic data included cardiac output; pulmonary capillary wedge pressure; and pulmonary arterial systolic, diastolic, and mean pressures. Body weight, height, and cardiac output were used to calculate cardiac index for each patient using the DuBois formula for body surface area. 15 For 1A candidates listed with the MCS, the MCS type (ie, LVAD, total artificial heart, extracorporeal membrane oxygenation, intra-aortic balloon pump, etc) was determined. The MCS justification subcriterion (acute hemodynamic decompensation, elective 1A time for stable durable LVADs, or objective device malfunction) was also determined. For status 1A candidates listed with high-dose/multiple inotrope therapy (and not receiving MCS), qualifying hemodynamic data and inotrope doses from the 1A justification form were analyzed. Data entry errors for inotrope doses, which were a priori defined as >200% maximum dose, were excluded.
WHAT IS NEW?
• This study demonstrates that inotrope therapy is an important contributor to the current excess of status 1A adult heart transplant candidates. • The number of candidates being listed as status 1A with inotropes is increasing while the doses of inotropes have declined.
• Status 1A inotrope candidates now survive substantially longer on the waitlist relative to status 2 candidates compared to a decade ago, implying these candidates have become less urgent over time.
WHAT ARE THE CLINICAL IMPLICATIONS?
• If candidates who should be listed as status 1B or 2 are instead being overtreated and listed status 1A with inotropes, this practice may compromise the fairness and effectiveness of both the current heart allocation system and the modified system awaiting implementation.
• Alternative heart allocation systems that do not rely on therapy as a proxy for urgency should be developed.
Statistical Analysis

Trends in Listing Status and Justifying Support Therapies
Because the geographic sharing policy was implemented on July 12, 2006, we divided the data into the pre-geographic sharing period (July 12, 2000, to July 11, 2006 ) and postgeographic sharing (July 12, 2006, to July 11, 2015) . Trends in initial listing status, justifications, inotrope doses, and candidate characteristics for both time periods were analyzed using nonparametric tests for change in proportions or means by year. 16 Because our data consisted of candidates nested within centers, hierarchal logistic regression models with fixed effects by center were estimated for both the pre-geographic sharing and post-geographic sharing time periods to provide adjusted trends in the odds of status 1A listing over time. We chose center-level fixed effects over random effects to control for unmeasured center-specific listing practices that could confound the effect of listing year. This method produces an estimate that can be interpreted as the average within-center effect of time on the odds of listing 1A. We included data from July 12, 2005, to July 11, 2006 , in both models, because the year before policy implementation is the appropriate reference year for measuring the geographic sharing policy effect. We kept all controlling candidate covariates detailed above in the model except for highly collinear covariates with correlations >0.7 where we removed the collinear covariate with the highest variance inflation factor. We purposefully did not include supportive therapies a patient was receiving as covariates in the model (eg, MCS, inotropes, ventilation) because the therapies are part of the causal pathway to status 1A listing.
To specifically examine trends in the use of inotropes to list candidates at status 1A, we repeated our analysis for candidates listed with either inotropes or no support (ie, excluding patients receiving MCS, mechanical ventilation, or granted status 1A or 1B with exceptions). This subgroup analysis isolates the effect of time on the odds a candidate was listed at status 1A with inotrope therapy as compared with being listed at status 1B with inotrope therapy or listed at status 2 with no support. Finally, for comparison, we examined trends in the last status of transplant recipients over time.
Waitlist Mortality of Status 1A Inotrope Candidates Over Time
We analyzed changes in the risk of candidate death or deterioration on the waitlist of candidates listed as status 1A with inotropes using a Fine-Gray regression with competing risks of transplantation and delisting. 17 The Fine-Gray subdistribution hazard model directly estimates the ability of status to predict death or deterioration on the waitlist after accounting for the different rates of transplantation and delisting among status groups. 18 We elected not to control for other covariates previously associated with death on the waitlist 2, 9 because our goal was to analyze status as a single predictor for urgency. Given the known improvements in the overall waitlist survival of all heart transplant candidates over time, 7 our main outcome was the subhazard ratio of death or deterioration for status 1A candidates relative to status 2 candidates. To assess trends in waitlist mortality within each time period, we divided both the presharing and postsharing periods into 2 equal halves. This approach allowed us to assess status 1A inotrope candidate waitlist survival in the context of increasing median status 1A waiting time over time and indirect effects of the expansion of CF-LVAD therapy. [7] [8] [9] [10] 19 Cumulative incidence functions of death or deterioration were estimated for each listing status and time period combination for the first 400 days after listing. To assess the robustness of our waitlist survival findings, we performed the following sensitivity analyses: we (1) changed the main outcome to death on the waitlist and added delisting attributable to deterioration as an additional competing risk, (2) added any type of ventricular assist device (VAD) implantation as a competing risk, (3) controlled for known risk factors for death or deterioration on the waitlist, and 4) estimated cause-specific hazard ratios.
All analyses were performed with Stata, version 15 (StataCorp, College Station, TX). Our study was exempt from institutional review board review as a reanalysis of a publicly available data set. The results of the multilevel logistic regression models for status 1A listing can be found in Tables 1 and 2 . In the pre-geographic sharing period, there was no significant change in the adjusted odds that a transplant program listed a candidate at status 1A (adjusted odds ratio 0.98, 95% confidence interval [CI], 0.78-1.23). However, in the post-geographic sharing period, the adjusted odds that a transplant program listed a candidate status 1A increased 117% (adjusted odds ratio, 2.17; 95% CI, 1.82-2.58) over 9 years. For candidates listed with either inotropes or no support, there was an 82% increase in the odds of listing status 1A with inotropes (adjusted odds ratio, 1.81; 95% CI, 1.39-2.38). Candidate characteristics used in adjusted models are summarized in Table  I in the Data Supplement, and the fully adjusted models can be found in Table II 
RESULTS
Unadjusted and Adjusted Trends in Status 1A Listing and Recipients
Inotrope Doses and Hemodynamics of High-Dose and Multiple Inotrope Status 1A Candidates
For status 1A candidates listed using high-dose or multiple inotropes as justification (not receiving MCS), In contrast, candidates listed with a single high-dose inotrope had relatively stable inotrope doses over time, the mean dose of high-dose dobutamine dose candidates declined 4% (P=0.005), whereas the milrinone dose was unchanged (P=0.63; Figure IV 
Waitlist Survival of Inotrope Candidates
In the 2 pre-geographic sharing time periods, status 1A inotrope candidates had a 130% and 95% higher risk of dying or delisting because of illness than status 2 candidates (Table 3; Figure 4 ; Table III in the Data Supplement). However, immediately after geographic sharing (July 12, 2006 , to December 31, 2010), the risk of death or deterioration for status 1A inotrope candidates was only 33% higher than status 2 candidates (subhazard ratio, 1.33; 95% CI, 1.08-1.63), representing a 62% reduction in risk when compared with the last 3 years before geographic sharing (July 12, 2003, to July 11, 2006) . During January 1, 2011, to July 11, 2015, status 1A inotrope candidates had a 25% higher risk of death or deterioration compared with status 2 candidates (subhazard ratio, 1.25; 95% CI, 1.07-1.47), representing a 70% reduction in risk relative to pre-sharing. There was small but statistically significant trend toward subsequent VAD implantation among candidates initially listed as status 1A with inotropes alone across the four time periods (19.2%, 22.8%, 23.5%, 23.2%, P<0.001 for trend). However, a similar pattern of reduction of relative status 1A mortality was observed in all sensitivity analyses, including adding VAD implantation as a competing risk (Tables IV  through VII in the Data Supplement) .
DISCUSSION
In this analysis of all 46 853 adults listed for heart-alone transplantation from 2000 to 2015, we show that the odds that a transplant program used inotropes to list a heart transplant candidate status 1A increased 82% since expansion of geographic sharing of hearts in 2006. Multiple inotrope listings drove this trend, responsible for >150 of the excess status 1A candidates listed each year. During this time period, the cardiac index of these candidates increased only slightly despite a large decrease in inotrope dose. The transplant-free waitlist survival of status 1A inotrope candidates substantially improved relative to status 2 candidates. Taken together, these trends indicate that overtreatment of less urgent heart transplant candidates with multiple inotropes contributes significantly to the current excess number of status 1A candidates. Before our report, the preponderance of status 1A candidates currently on the waitlist has mainly been attributed to improvements in MCS, specifically CF-LVADs. Therefore, it has been assumed that these CF-LVAD candidates are the main drivers of the dilution of status 1A urgency. 6, 9, 20 However, we demonstrate that the trend toward excess 1A listings was also driven in large part by increases in the rate of listing multiple inotrope candidates. In our multivariate logistic regression model, this trend toward status 1A listing with inotropes could not be explained by changes in any candidate factors or center-level effects. This result implies that the trend toward status 1A inotrope use is best described as a change in average listing practice within centers over time.
After establishing that status 1A inotrope listings significantly increased, we investigated trends in the medical urgency of these candidates over the same time period. Physiologically, we found that the inotrope doses used to list these multiple inotrope candidates declined substantially (29% to 55%), whereas the cardiac index and filling pressures of these candidates improved. This trend toward improved physiology was paired with substantial reductions in the risk of death or deterioration as estimated by a competing risks model. 19 and more frequent delisting in favor of CF-LVAD placement.
We think that the most likely explanation for these findings is a shift in transplant program-listing practice over time. Specifically, it seems that programs are overtreating less urgent candidates with multiple inotropes to obtain 1A status. Increased competition for transplantable hearts is a plausible explana- Regardless of the exact mechanism, the net effect of both the trend toward increased CF-LVAD and multiple inotrope use is a breakdown of the supposed urgencybased stratification of adult heart transplant candidates. The final rule, issued by the department of health and human services, requires that allocation systems rank candidates from most to least medically urgent. 21 Undoubtedly, there are truly critically ill candidates being listed urgently with multiple inotropes. However, our data suggest that these truly sick candidates may not receive the priority for transplantation they deserve because they must compete with less urgent candidates.
Our results have implications for the recently accepted 6-status allocation system, which breaks status 1A up in to 3 new status levels in an effort to alleviate the excess of status 1A candidates. 8 In December 2016, hemodynamic and inotrope requirements were added to this proposal. We have recently shown that at least 74% of multiple inotrope candidates listed from 2010 to 2015 will be disqualified from high priority listing status by this shock requirement. 22 At face value, this shock requirement seems to be a solution to the problematic trends toward overtreatment with inotropes described in this article. However, as stated by the Organ Procurement and Transplant Network, the expected impact of the shock requirement is based on current behavior and practices and (this has raised concern) that the proposal would influence practitioners to behave differently than they currently do. 8 We think it unlikely that transplant programs that currently overtreat with multiple inotropes will passively accept the new rules and compliantly list the majority of their candidates at status 6. Rather, we agree with others that predict transplant centers will shift practices once again and use surgically placed MCS devices because these therapies are exempt from the shock requirement.
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Study Limitations
Our analysis has several limitations. First, although the Scientific Registry of Transplant Recipients database contains a record of all candidates listed for heart transplantation, we do not have data on all the patients with advanced heart failure who would benefit from transplant. Therefore, our conclusions only apply to the population of candidates fortunate enough to be listed for heart transplantation, not all those who could potentially benefit. Second, we may be missing candidate characteristics in our data, which might explain the increase in multiple inotrope use for status 1A listing. Third, the effect of improved heart failure therapies in general from 2000 to 2015 Subhazard ratios estimated with a Fine-Gray competing risks regression model (see Table III in the Data Supplement for full model results). 95% confidence intervals given in parentheses.
has led to improvements in survival in advanced heart failure patients, which make interpretation of the relative improvement in status 1A inotrope candidate waitlist outcomes difficult.
Conclusions
After the wider geographic sharing of hearts in 2006, transplant program used inotropes to list adult heart transplant candidates at status 1A much more frequently. Multiple inotrope listings were responsible for >150 excess status 1A listings in 2015 compared with 2006. During this time period, the cardiac index of these patients increased slightly despite up to a 55% decrease in inotrope dose. After geographic sharing, status 1A inotrope candidates were >60% less likely to die or deteriorate on the waitlist compared with status 2 candidates. Overtreatment of less urgent adult heart candidates with multiple inotropes contributes significantly to the current excess of status 1A candidates.
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